Appointments at Genzyme, Amarin and Hard To Treat Diseases – People on the move
On January 1 2010 Joseph Zakrzewski will step down as CEO of Xcellerex to become the executive chairman of Amarin. Zakrzewski spent 17 years at Eli Lilly before becoming chief operating officer at Reliant Pharmaceuticals.
When he was at Reliant the company developed and launched Lovaza, leading to the acquisition by GlaxoSmithKline in 2007. Following this he became CEO of Xcellerex and also serves on the boards of directors at Promedior and Zelos Therapeutics.
Genzyme has appointed Robert Bertolini to its board of directors. Bertolini’s appointment comes after the board’s nominating and governance recommended that another member was added, bringing the total up to nine people.
Before its merger with Merck & Co Bertolini was executive vice president (VP) and chief financial officer at Schering-Plough. Bertolini also spent 20 years at PricewaterhouseCoopers, culminating in him leading the global pharmaceutical industry practice.
Hard To Treat Diseases (HTDS) has appointed Rudolph Dahl as a marketing advisor. Dahl has more than 30 years experience in governmental relations, contracting and policy representation and will assist with quickly supplying HTDS’ H1N1 vaccine to Africa, South America and Asia.
Former Wyeth executive Thomas Hofstaetter has been appointed as chief operating officer of Vaxinnate. Hofstaetter led corporate business development at Wyeth and has 30 years experience in the pharma industry at companies including Aventis and Hoechst.
Concert Pharmaceuticals has appointed Lijun Wu to the newly created position of VP, biology. Wu has more than 15 years experience in pharma and biotech R&D, most recently at Resolvyx Pharmaceuticals.
